No  Site  Stage of cancer   Title of study Principal investigator  Details of trial  Status
1.  Breast  STAGE 4, BRAIN METS, 2nd LINE, HER2 + ASLAN001-006: A phase II single arm trial to assess the efficacy of ASLAN001 plus capecitabine in previously irradiated, progressing central nervous system (CNS) metastases for HER2 positive breast cancer patients. Dr Yap Yoon Sim   NA Open 
2. Breast  METASTATIC - 2ND LINE / HER2 (-), ER (+) Bayer 17096: A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases  Dr Kiley Loh NCT02258451   Open
3. Breast TNBC, non-metastatic, 1st line, neoadjuvant

MK3475-522:   A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as neoadjuvant therapy and Pembrolizumab vs Placebo as adjuvant therapy for Triple Negative Breast Cancer

Dr Rebecca Dent  NCT03036488  Open
 4. Breast HER2-, Hormone Receptor +, Advanced Breast Ca

CBYL719X2402:  A Phase II, Multicenter, open-label, two-cohort, non-comparative study to assess the efficacy and safety of Alpelisib plus Fulvestrant or Letrozole based on prior endocrine therapy, in patients with PIK3CA mutant hormone receptor (HR) positive, Her2-negative advanced breast cancer (aBC), who progressed on or after CDK 4/6 inhibitor treatment.

 Dr Yap Yoon Sim  NCT03056755  Open


Last updated on Jan 2018.